Compare Heron Therapeutics Inc (HRTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs WD 40 Company — how do they compare? Heron Therapeutics Inc trades at $0.39 (market cap $68.01M), while WD 40 Company trades at $200.72 (market cap $2.73B). The key difference: WD 40 Company is far larger — about 40.1× Heron Therapeutics Inc's market cap, and WD 40 Company pays a 2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and WD 40 Company for 22 Days on average.
| HRTX | WDFC | |
|---|---|---|
Market Cap | $68.01M | $2.73B |
Volume | 1,891,941 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $264.91 |
52-Week Low | $0.27 | $187.52 |
Typical Hold Time | 35 Days | 22 Days |
Enterprise Value | $174.75M | $2.79B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
